Bladder cancer is the sixth most common cancer in the United States after lung cancer, prostate cancer, breast cancer, colon cancer, and lymphoma. Of the roughly 70,000 new cases annually in the United States, about 53,000 are in men and about 18,000 are in women.
Bladder cancer typically presents with gross or microscopic hematuria. Less commonly, patients may complain of urinary frequency, nocturia, and dysuria, symptoms that are more common in patients with carcinoma in situ. Patients with upper urinary tract urothelial carcinomas may present with pain due to obstruction by the tumor.
Bladder cancer is divided into muscle-invasive and nonmuscle-invasive disease, based on invasion of the muscularis propria (also referred to as the detrusor muscle), which is the thick muscle deep in the bladder wall. Muscle-invasive disease is much more likely to spread to other parts of the body and is generally treated by either removing the bladder or treating the bladder with radiation and chemotherapy.
Approximately 20% to 30% of patients with newly diagnosed bladder cancer will present with muscle-invasive bladder tumors . Options for treatment of muscle-invasive bladder tumors are limited, with surgical removal of the bladder as one primary option. Chemotherapies have demonstrated limited effectiveness in treating invasive forms of bladder cancer. Often patients with invasive forms of bladder cancer are referred to clinical trials as the best option.
MTG is focused on exploring the REIC technology platform in invasive bladder cancer with our MTG-202 vector technology. The REIC technology has demonstrated significant potential to treat invasive bladder cancer without impacting the quality of life of patients.